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The Papanicolaou Society of Cytopathology has developed a
set of guidelines for pancreaticobiliary cytology including indi-
cations for endoscopic ultrasound (EUS) and fine-needle aspi-
ration (FNA) biopsy, techniques for EUS-FNA, terminology
and nomenclature to be used for pancreaticobiliary disease,
ancillary testing, and post-biopsy management. All documents
are based on expertise of the authors, literature review, dis-
cussions of the draft document at national and international
meetings, and synthesis of online comments of the draft docu-
ment. This document selectively presents the results of these
discussions.
This document summarizes recommendations for the clinical and
imaging work-up of pancreatic and biliary tract lesions along with
indications for cytologic study of these lesions. Prebrushing and
FNA requirements are also discussed. Diagn. Cytopathol.
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The work-up of a biliary stricture, pancreatic cyst, or
solid mass requires a carefully orchestrated sequence of
clinical and imaging studies that may be followed by
cytologic investigation. The current document describes
the clinical work-up along with imaging studies as recom-
mended by the Papanicolaou Society of Cytopathology.
Recommendations are made for the appropriate use of
bile duct brushing cytology obtained through endoscopic
retrograde cholangiopancreatography (ERCP) and endo-
scopic ultrasound and fine-needle aspiration (EUS-FNA)
cytology of mass lesions in the pancreas. Prebrushing and
FNA requirements are discussed including consent forms
and information to be included in the requisition form for
optimal cytologic evaluation of pancreatic and biliary
tract specimens.
Presentation and Clinical Evaluation
A variety of clinical and laboratory features are associ-
ated with malignancy of the biliary tract or pancreas.
Newly diagnosed late onset diabetes mellitus or unex-
plained acute pancreatitis in an older individual require
work-up that often includes exclusion of pancreatic car-
cinoma.1 Similarly, the development of jaundice, pruri-
tus, or cholestasis not explained by underlying liver or
gallbladder disease or choledocholithiasis should initiate
an evaluation for neoplasia of the hepaticobiliary tract.1–3
In addition, clinical investigation and imaging studies
may be initiated for a variety of reasons including
abdominal pain that radiates to the back, anorexia,
weight loss, new onset diabetes, steatorrhea, presence of
newly discovered metastatic disease, or abnormal liver
enzymes. Laboratory and imaging studies play an impor-
tant role in the evaluation of patients with pancreatico-
biliary lesions.
Patients with suspected neoplasia of the pancreaticobili-
ary tract should receive the following:
1. A thorough history and physical examination
including identifying risk factors for malignant
causes and for benign explanations for a stricture or
cyst (e.g., chronic pancreatitis, PSC/IBD, autoim-
mune disease, etc.).
2. Laboratory studies to detect elevations of serum bil-
irubin and alkaline phosphatase as well as other
liver chemistries.
3. Selective use of serum tumor markers including
CA19-9 and CEA.4–6
4. Imaging studies.
5. Selective use of serum IgG4 when autoimmune dis-
eases are suspected.
Imaging Studies
Imaging modalities used in evaluating patients with clini-
cally suspected pancreaticobiliary neoplasia include
abdominal ultrasound (AUS), selective use of computer-
ized tomography (CT), ERCP, EUS, and/or magnetic res-
onance imaging (MRI). When used, MRI may include
magnetic resonance cholangiopancreatography (MRCP)
and, occasionally, magnetic resonance angiography
(MRA).1–3 Positron Emission Tomography (PET) CT is
recommended for staging pancreatic cancer if curative
surgery is contemplated. It is not currently recommended
for diagnosis.
AUS is the least invasive and lowest cost imaging tech-
nique available for evaluation of obstructive jaundice and
biliary obstruction by demonstration of biliary duct dilata-
tion when taking into consideration the patient’s age and
history of prior cholecystectomy (both of which can affect
ductal diameter). It may also disclose obvious liver
metastases. EUS is operator dependent and has a rela-
tively poor sensitivity for detecting small neoplasms
within the pancreatic head.2,3 EUS can only see the pan-
creas in a limited manner, usually due to intervening
ultrasound-attenuating abdominal wall fat, the depth of
penetration to see the retroperitoneum and/or overlapping
gas-filled stomach or loops of bowel. Recent advances in
ultrasound technology including color power Doppler
ultrasonography, ultrasonographic angiography, contrast
harmonic imaging, and three-dimensional ultrasonography
may improve the sensitivity and specificity of the ultra-
sound technique.7–13
Multi-phase computed tomography (CT) scanning of
the abdomen utilizing fine cuts through the pancreas with
contrast enhancement (“pancreas protocol” CT scanning)
is more sensitive and specific than AUS for detecting bili-
ary obstruction, and has the ability to determine the site
and cause of obstruction. CT is strongly recommended as
the primary modality for evaluating patients with sus-
pected malignant biliary obstruction, for both diagnosis
and staging. It also allows detection of liver metastases
and invasion of vascular structures as well as potential
lymph node involvement.14–24 Multidetector CT (MDCT)
may improve accuracy above that obtainable by helical
CT. New CT techniques may further increase the sensitiv-
ity of CT for pancreatic neoplasia.25–28 MDCT relies
heavily on hypoperfusion seen in many adenocarcinomas,
and mass effect. Several studies have more recently
shown that smaller lesions on well-perfused tumors can
have a modest miss-rate with CT.
If CT findings are consistent with resectable pancreatic
carcinoma and the patient is felt to be otherwise an opera-
tive candidate, the patient may be referred directly for
surgery without further imaging or diagnostic testing,
although this clinical situation is rarely encountered. In
addition, this approach risks inappropriate surgery for
focal pancreatitis (including autoimmune pancreatitis) or
lymphoma. Transabdominal or CT-guided biopsy of the
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pancreatic mass may be requested when endoscopic tech-
niques are not readily available but had a lower perform-
ance in a randomized trial.29
When CT scanning reveals definitive evidence of unre-
sectability for pancreatic or biliary tract cancer or if the
patient is either a nonoperative candidate due to comor-
bidities or in cases where surgery is planned but delayed
(i.e., in patients undergoing neoadjuvant therapy, patients
needing more involved evaluation and/or stabilization of
other medical issues, etc.), the placement of a biliary stent
is typically performed using ERCP for palliation, or to
reduce cholestasis to allow adjuvant therapy.
Recently, neoadjuvant chemotherapy and/or radiation is
being utilized in potentially resectable or borderline
resectable patients and usually requires a definitive preop-
erative tissue diagnosis. Transabdominal CT or ultrasound
biopsy of metastatic disease may be sufficient; in nonme-
tastatic disease, EUS-guided FNA is a higher yield
maneuver and may be obtained on either the primary site
or a metastatic site reachable with EUS. EUS is now the
procedure of choice for evaluating and sampling pancre-
atic masses at many institutions.
Multiple MRI techniques exist for evaluation of the
pancreas for neoplastic disease. These include MRI,
MRCP, or MRA. Traditional abdominal MRI appears to
be a highly accurate modality for staging pancreatic carci-
noma but does not appear to be more specific or sensitive
than CT.30–32 Modifications of the MRI technique such as
MRCP and MRA may improve sensitivity and specificity
and may be useful for Vascatar staging.33–36 MRCP pro-
vides much better ductal imaging, illustrating the level
and cause of the obstruction more reliably than CT, but
determination of benign versus malignant strictures has
weaker performance. It is also more reliable than CT at
differentiating solid versus cystic lesions in the pancreas
and determining morphology of the cyst and communica-
tion with the pancreatic duct. It is weaker at detecting
calcifications than CT, which may point to a benign
explanation for the stricture or cyst.
Diagnostic Work-Up for Cysts of the Pancreas
The most important determination in the investigation of
a pancreatic cyst is whether the cyst is mucinous (prema-
lignant) or nonmucinous (serous, developmental, and
inflammatory).
This distinction by preoperative imaging has been disap-
pointing, but imaging classification systems have been pro-
posed.37 Small incidental cysts can usually be managed
expectantly.38 Serous cystadenomas may have characteristic
imaging and clinical features allowing their recognition
without further investigation.39 Such neoplasms demon-
strate a microcystic “honeycomb” appearance with a central
scar. CT scans are frequently the first test used to evaluate a
pancreatic cyst. ERP and EUS can be used if further evalua-
tion is deemed necessary.39
A multidisciplinary conference held at Sendai, Japan,
in 2005 led to published guidelines in 2006 (the “Sendai
Guidelines”), which established algorithmic protocols for
the work-up and management of patients with pancreatic
neoplastic mucinous cysts.40 These guidelines were
updated in 2010 and published in 2012 (the 2012 Guide-
lines)41 (Fig. 1). The guidelines base management primar-
ily on clinical and imaging findings with conservative
management of small cysts (<3 cm) occurring in patients
without high-risk clinical or imaging findings.
Patients considered at high risk for malignancy are those
with obstructive jaundice and a cystic lesion in the head of
the pancreas, an enhancing solid component within the cyst
or a main pancreatic duct 10mm in diameter. These
patients are triaged to surgery without preoperative tissue
confirmation. If these high-risk features are absent, the
patient should be further evaluated for the presence of pan-
creatitis or worrisome imaging features.
Worrisome imaging features warranting endoscopic
ultrasound and consideration of biopsy include a cyst
equal to or greater than 3 cm in diameter, thickened/
enhancing cyst wall, a main pancreatic duct 5–9 mm in
diameter, a nonenhancing mural nodule, or an abrupt
change in the caliber of the main pancreatic duct with
distal pancreatic atrophy. Patients with pancreatitis should
also be referred for endoscopy. When EUS discloses a
definitive mural nodule, a main duct with features suspi-
cious for involvement by the cystic lesion or cytology
suspicious or positive for malignancy, the patient should
be referred for surgery.
In the absence of high-risk and worrisome features, further
management depends on the size of the cystic lesion. Cysts
under 1 cm in size should undergo CT/MRI reexamination in
two to three years. Cysts between 1 and 2 cm in size should
have yearly CT/MRI examinations for two consecutive years
if no significant change is noted; the interval can be length-
ened. Patients with cysts between 2 and 3 cm in maximum
dimension should undergo EUS examination in 3–6 months.
Then have repeat MRI examinations at lengthened intervals
alternating with EUS as appropriate. Young fit patients may
be considered for surgery. Patients whose cysts are over 3 cm
in size should undergo repeat MRI examinations alternating
with EUS every 3–6 months. Surgery should be strongly con-
sidered as an alternative strategy in young fit patients.
Endoscopic Diagnostic Techniques
When endoscopic ultrasonography is available, it should be
used for preoperative staging in patients with suspected pan-
creatic carcinoma or cancer of the biliary tract. In addition, in
low to moderate suspicion cases (dilated ducts or unexplained
weight loss), it has high negative predictive value. Endo-
scopic ultrasonography is particularly useful when CT or MR
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findings are equivocal, in CT-resectable disease to screen for
subtle vascular involvement (especially in borderline surgical
candidates), or when unresectable disease is suspected and a
tissue diagnosis is needed.42 EUS demonstrates significant
advantages over CT and MR in establishing the presence of
vascular invasion.29,43–45 Endoscopic ultrasonography
appears to be complimentary to CT but EUS appears to be
superior for detecting small masses, evaluating for tumor
involvement of the superior mesenteric vein and the portal
vein and detecting lymph node metastases.29,43–45 The overall
staging accuracy of EUS for pancreatic adenocarcinoma is
between 90% and 100%. When compared with CT in this
population, EUS has a higher sensitivity for tumor detection.
For small (<16 mm) pancreatic masses, the sensitivity of
EUS for tumor detection approaches 100% compared with
66% using multidetector CT. Accuracy for resectability, as
determined by EUS, is 88%–100%.46,47 CT appears superior
to EUS when evaluating the SMA as EUS can only see this
vessel for a short distance beyond its origin, and for establish-
ing the presence of absence of distant metastases.29,43–45
Adjuncts to EUS, such as elastography and contrast harmonic
imaging, are promising to improve performance in selected
cases.
A key advantage of EUS is that EUS-guided FNA can be
performed as an integral part of EUS examination. This
allows definitive tissue acquisition and rapid diagnosis.
When EUS suggests resectability, EUS-guided biopsy may
not be necessary prior to definitive resection. However, in
many institutions, all solid pancreatic masses are aspirated
prior to surgery (to rule out lymphoma, autoimmune/focal
pancreatitis, and assess for other types of cancer beyond
adenocarcinoma). The requirement for tissue diagnosis in
this setting remains controversial. FNA of the mass does
have some advantages in that it may establish other diagno-
ses other than primary pancreatic adenocarcinoma and
allows for preoperative patient counseling. Many patients
in the current era also undergo neoadjuvant therapy preop-
eratively as well and, in general, most medical and radia-
tion oncologists will not treat a patient without a definitive
tissue diagnosis. It should be kept in mind that preoperative
EUS-guided FNA, while overwhelmingly safe and effec-
tive, has a small risk of complications including pancreati-
tis, infection of upstream obstructed ducts, and
hemorrhage. The potential for needle track tumor implanta-
tion is felt to be extremely small but still possible and
essentially restricted to body and tail masses sampled with
transgastric FNA (as the needle tracks site is resected when
transduodenal FNA is followed by a Whipple).48
The evaluation of cystic lesions of the pancreas has
historically been a clinical challenge. It is often difficult
to identify the type of cystic lesion present based on
cross-sectional imaging alone. Furthermore, CT is not
particularly helpful in the assessment of the potential
malignant character of cysts. MRCP is more helpful at
Fig. 1. Reprinted from Pancreatology, published online 2 May 2012, Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus
guidelines 2012 for the management of IPMN and MCN of the pancreas, copyright 2012, with permission from Elsevier.
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determining the presence of solid components and ductal
communication suspicious of IPMN, but small solid com-
ponents, calcifications, and septations may be missed.
Some lesions, such as serous cystadenomas, may have a
typical appearance that can be identified on cross-
sectional imaging, but in most cases, further evaluation is
needed.
In recent years, it has become clear that cyst fluid anal-
ysis may be more helpful than imaging morphology in
many cases. Because of the difficulty in assessment of
cystic lesions by cross-sectional imaging and the ease
with which pancreatic cyst fluid can be obtained through
EUS, the threshold for cyst aspiration by EUS is very
low. Although cystic lesions as small as 5–6 mm can be
successfully aspirated under EUS, most endoscopists do
not perform FNA for cystic lesions under 1–1.5 cm due
to the limited amount of fluid/cellular material available
for analysis. Cysts greater than 1–1.5 cm in size are com-
monly aspirated.49 The above criteria apply in the
absence of pancreatitis.
A prior history of pancreatitis may or may not prompt
a cyst evaluation if there is a strong suspicion that a
cystic lesion is a pseudocyst (especially if antecedent
imaging obtained before the episode of pancreatitis failed
to show the lesion); the lesions may be followed by serial
imaging. Pseudocysts obviously arising in acute pancreati-
tis are not generally aspirated for many reasons, including
low yield of finding another diagnosis, high overlap of
CA19-9 in pseudocysts versus mucinous lesions, and
higher chance of infection in the presence of thick fluid,
debris, and necrosis. If there is concern that a cystic
lesion may have led to an episode of pancreatitis, EUS
with FNA is often warranted.
Although all care should be individualized, worrisome
signs on EUS of cystic lesions include a size greater than
2 cm, intracystic nodularity, or associated solid compo-
nent or thick wall. Pain, pancreatic duct dilatation, jaun-
dice, and weight loss also may increase the chance of a
malignant cause, although many of these features can be
present in chronic pancreatitis. Thus, patients presenting
with cystic lesions larger than 2 cm, especially without a
history of pancreatitis, pancreatic, or bile duct enlarge-
ment and/or weight loss, should be strongly considered
for EUS with FNA.50
Endoscopic Retrograde Cholangiopancreatography
Although years ago, ERCP was considered to be a gold
standard for cystic lesions of the pancreas, and evaluation
of biliary strictures or a “double duct sign,” EUS and
MRCP have replaced it for many of these indications,
avoiding its risks, particularly pancreatitis, and infection
of cysts with contrast. It is now only rarely used as a pri-
mary tool for establishing the diagnosis of pancreatic ade-
nocarcinoma or work-up of pancreatic cysts. Currently,
ERCP is most useful clinically for providing relief of
obstructive jaundice by either plastic or metal biliary stent
placement. Brush cytology (mono-sampling) from biliary
strictures or, to a lesser extent, pancreatic duct strictures
is still widely performed but has a much lower yield than
EUS-FNA.
Diagnostic Techniques for Suspected
Cholangiocarcinoma
EUS has not been shown to be superior to other imaging
and sampling techniques for identification of cholangio-
carcinoma. EUS identification of cholangiocarcinoma is
often technically difficult even for experienced endoso-
nographers, for many reasons. Early cholangiocarcinoma
can be laterally spreading along the duct, with minimal
“mass” or wall thickening. FNA of a thin-walled mass
has low yield. Sizable tumors at the hilum have good
yield with trans-bulb FNA of either the mass or periportal
lymph nodes. Tumors above the hilum are not generally
evaluable with EUS.49 Intraductal ultrasonography per-
formed at the time of ERCP may add additional informa-
tion in patients suspected of pancreaticobiliary
malignancies especially cholangiocarcinomas, but per-
formance characteristics and accuracy for benign versus
malignant strictures appear poor.
Post-Imaging Studies
Following studies establishing an imaging diagnosis of
pancreatic and/or pancreaticobiliary malignancy, some
clinicians may desire tissue confirmation. Such tissue con-
firmation can be performed by either abdominal CT or
ultrasound-guided FNA, ERCP-guided bile duct or pan-
creatic duct brushings, or EUS-guided FNA.51 The value
and clinical necessity of such biopsies remains controver-
sial. In the majority of cases, these techniques are easily
performed but have variable degrees of sensitivity and
specificity. Size criteria, and location criteria for the utili-
zation of image-guided biopsy techniques are controver-
sial, but EUS has become the dominant technique for
evaluating and performing biopsy on known or suspected
pancreatic masses. Most pancreatic neoplasms are adeno-
carcinoma, but the differential diagnosis includes pancre-
atic neuroendocrine tumors, autoimmune pancreatitis, and
metastatic disease (among other causes). Given the need
for tissue diagnosis prior to neoadjuvant or palliative
chemotherapy, FNA is almost always performed for solid
pancreatic tumors. Biopsy is most commonly performed
through EUS guidance or CT guidance. EUS-FNA has
similar, and possibly superior, sensitivity to CT-guided
FNA.52 There is also the possibility of an increased risk
of peritoneal carcinomatosis by tumor seeding using
the percutaneous approach (which may be reduced via
EUS-guided FNA).53 The use of EUS in staging pancre-
atic cancer allows for identification of resectability and
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FNA in the same procedure. EUS diagnosis of pancreatic
masses can be limited in the setting of recent acute pan-
creatitis (<4 weeks), chronic pancreatitis, a prominent
ventral/dorsal split of the pancreatic head, or in diffusely
infiltrating cancer (all of which distort the underlying
parenchyma, which EUS relies on to see abnormal masses
via contrast between the two).54
Techniques for the work-up of solid and cystic lesions
of the pancreas vary. Cysts should be aspirated with as
much fluid being drawn off as possible and sent for cyto-
logic, chemical, and molecular analysis; CEA appears to
be most helpful and would be the priority when limited
fluid is obtained. Multiple FNAs of solid lesions should
be obtained if immediate onsite cytologic evaluation is
not available. If an onsite cytopathologic evaluation is
available, then intraprocedural cytologic evaluation should
be performed to ensure adequacy of tissue samples.
Pre-FNA Requirements
Informed Consent Form for Pancreaticobiliary FNA
Informed consent is the communication process between
the patient and the physician that results in the patient’s
agreement to undergo a particular procedure and/or treat-
ment.55–61 The principle of informed consent is a legal
principle and based on the belief that a competent indi-
vidual has the right to determine what is done to her or
him.55–61 All medical care including the procuring of lab-
oratory tests requires at least an informal informed con-
sent except when a patient is incompetent to make
decisions or has abrogated that right.55–61 Legislation reg-
ulating conditions under which informed consent must be
obtained varies from state to state.55,59,60 Due to this vari-
ability, providers including pathologists, radiologists,
endoscopists, and surgeons need to be familiar with the
informed consent policies based on state regulations. The
AMA recommends that the following be disclosed and
discussed with the patient:
1. The patient’s diagnosis, if known.
2. The nature and purpose of the proposed treatment
or procedure.
3. The risks and benefits of a proposed treatment or
procedure.
4. Alternate options.
5. The risk and benefits of the alternate treatment or
procedure.
6. The risks and benefits of not receiving or under-
going the treatment or procedure.
Unfortunately, informed consent procedures are imper-
fect.55,56 Less than half the population understands com-
monly utilized medical terms, which limits the value to
the patient of many informed consents. It is often not fea-
sible to discuss all alternate options in the limited time
available in the preprocedure setting, especially in the era
of open-access radiology and open-access endoscopy.62–66
The use of written information supplied during the
informed consent procedure may increase patient compre-
hension.66–70 No matter what form informed consent
takes, it must be clearly understood by the patient and
adequate opportunity for patient questions must be
available.70
Informed Consent Recommendations
a. Use of informed consent materials including written
documents describing the FNA procedure and
potential risks and complications may be
considered.
b. The possibility of bleeding, allergic/cardiac/respira-
tory reaction, hemorrhage, and/or perforation should
be mentioned.
c. Information should be presented in a manner to
facilitate patient understanding.
d. Informed consent should include telling the patient
that the results may be noncontributory (unhelpful).
e. Estimates of accuracy such as false-negative or
false-positive rates are not mandatory and should be
discussed only if the practitioner believes that they
would facilitate patient comprehension.
Information Required on the Requisition Form that
Accompanies a Pancreatic FNA Request
Federal regulations in the United States require that cer-
tain identifying information be provided to laboratories
with all specimens submitted for laboratory testing.71
These requirements include the following:
1. Name and address of person requesting the test.
2. Patient’s name and/or unique identifier.
3. Patient gender.
4. Patient age or date of birth.
5. Name of the test to be performed.
6. Specimen source and location, that is, “head of
pancreas.”
7. Date of specimen collection.
8. Any additional relevant information (this request is
usually construed to mean clinical history).
Additional relevant information, which when included
is helpful for specimen evaluation, should be conveyed to
the pathologist in the clinical or additional information
section. This information may include precise site of the
lesion being sampled, the tissue traversed in FNA (trans-
gastric, transduodenal, etc.), the presence or absence of
bile duct or pancreatic duct stricture, and the size of the
lesion. The solid or cystic nature of the lesion should also
be included in the clinical history. In cystic lesions, the
configuration of the cyst, whether single or multilocular,
is helpful for pathologic examination.72 Similarly, the
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ultrasonographic, CT, or MR characteristics of the lesion
should be included as additional information, including
the presence of vascular or other organ invasion or known
metastatic disease. History of prior malignancy should be
included, as well as history of alternative diagnoses (alco-
holic abuse, pancreatitis, PSC/IBD, autoimmune disease),
if relevant. The occurrence of recent pancreatitis or chol-
angitis, and the presence of a stent, should also be
included with relevant history, as inflammation or stent-
induced atypia may need to be taken into consideration.
Clinical suspicion of neuroendocrine tumor or lymphoma
should be indicated, as it requires special stains/media.
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